Lifebit is a technology company.
Lifebit has raised $68.0M across 2 funding rounds.
Lifebit has raised $68.0M in total across 2 funding rounds.
Lifebit has raised $68.0M in total across 2 funding rounds.
Lifebit's investors include AngelList, BEENEXT, DST Global, Fundamentum, Matrix Partners India, Tiger Global Management, Kunal Shah, Eurazeo, Hugues De Braucourt.
Lifebit is a precision medicine software company headquartered in London, UK, that builds enterprise data platforms for organizations handling sensitive genomic and biomedical datasets.[1][2] Its core products include Lifebit CloudOS, a federated solution for FAIR omics and biomedical analysis that enables faster, cheaper, and secure scaling in existing data environments, and Lifebit AI-Engine, which uses deep learning to analyze drug responses, repurpose drugs, validate targets, and optimize vaccines.[1][3] Lifebit serves leading life sciences organizations, pharmaceutical companies, and healthcare providers like Flatiron Health, addressing the challenge of accessing and analyzing siloed biomedical data without risky data movement.[1][2] The platform supports secure federated analysis, data transformation to standards like OMOP, trusted research environments (TREs), and AI-driven cohort building, with growth evidenced by partnerships expanding into Japan for real-world oncology data and access to 270M+ harmonized datasets.[1][3]
Lifebit was founded to tackle the growing challenge of utilizing vast amounts of siloed biomedical data generated in precision medicine, where data access has become a major barrier to curing diseases.[2] Led by Dr. Maria Chatzou Dunford, Chief Executive Officer, the company emerged from expertise in bioinformatics, clinical research, and engineering, developing patented technology for in-situ federated analysis on distributed datasets.[2] Early focus centered on creating secure platforms for genomics and health data, evolving into a full ecosystem with CloudOS and AI-Engine, backed by investors and memberships in key industry groups.[2] Pivotal moments include multi-year partnerships like with Flatiron Health, now extending to Japan for cancer care research using TRE technology on real-world data.[1]
Lifebit rides the precision medicine and federated learning wave, where explosive growth in genomic, omics, and real-world health data (e.g., from EHRs like Epic) outpaces traditional centralized analysis due to privacy regulations and silos.[2][3][4] Timing is ideal amid rising demand for secure, scalable data platforms post-GDPR/HIPAA evolutions and AI advancements in drug discovery, enabling global collaborations without data centralization risks.[1][5] Market forces like biopharma's push for faster target validation and multi-ancestry genomics favor Lifebit's in-situ federation and AI, as seen in oncology RWD partnerships.[1][3] It influences the ecosystem by standardizing TREs, OMOP transformations, and marketplaces, democratizing access for researchers and accelerating discoveries in cancer care and beyond.[2][4]
Lifebit is poised to dominate federated biomedical data platforms as AI agents and multi-omics integration become standard in precision medicine.[3] Next steps likely include expanding TRE marketplaces globally, deeper EHR federations, and AI enhancements for real-time clinical trials, fueled by partnerships like Flatiron in Japan.[1] Trends like regulatory pushes for data interoperability and AI-driven drug repurposing will amplify its momentum, potentially evolving it into a central hub for 1B+ global health datasets. This positions Lifebit as a key enabler in overcoming data silos, directly advancing its mission to make biomedical data a tool for curing diseases rather than an obstacle.[2]
Lifebit has raised $68.0M across 2 funding rounds. Most recently, it raised $60.0M Series B in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $60.0M Series B | AngelList, BEENEXT, DST Global, Fundamentum, Matrix Partners India, Tiger Global Management, Kunal Shah | |
| Apr 1, 2020 | $8.0M Series A | Eurazeo, Hugues De Braucourt |